<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875654</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC 06 25</org_study_id>
    <nct_id>NCT00875654</nct_id>
  </id_info>
  <brief_title>Intravenous Stem Cells After Ischemic Stroke</brief_title>
  <acronym>ISIS</acronym>
  <official_title>Cell Therapy by Intravenous Injection of Mesenchymal Stem Cells After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commissariat à l'Energie Atomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate feasibility and tolerance of the intravenous
      injection of autologous mesenchymal stem cells for patients presenting an ischemic stroke
      (less than 6 weeks).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is the leading cause of acquired adult disability. Except the hospitalization in
      stroke units, only thrombolysis has been shown to be efficient to treat acute ischemic stroke
      in the first three hours after the onset. Increasing brain plasticity after stroke represents
      an important alternative strategy. Cell therapy provides a functional improvement after
      cerebral ischemia in rodent models. This &quot;restorative&quot; therapy aims to replace destroyed
      cerebral tissue with a stem cells graft. Despite these encouraging experiments, we do not
      know yet the best way of administration of the stem cells, the best dose and the optimal
      delay of the graft. The pioneer clinical studies failed to reproduce this benefit for
      patients probably because of the limited number of studied patients. Therefore, more
      translational studies are needed to improve our knowledge in this promising field. Among
      different cell sources, mesenchymal (or stromal) stem cells (MSC) derived from bone marrow
      offer the advantage of arising from a non tumoral and no modified source and are not sources
      of immunological or ethical problems.

      Our research project involves a development of cell therapy in a phase IIa clinical trial of
      feasibility and safety in patients (randomised, controlled, open, with 3 parallel groups).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">October 20, 2017</completion_date>
  <primary_completion_date type="Actual">October 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke</measure>
    <time_frame>2 weeks, 1, 2, 4, 6 months and 1, 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and functional effects of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke</measure>
    <time_frame>2 weeks, 1, 2, 4, 6 months and 1, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the most effective dose of stem cells</measure>
    <time_frame>2 weeks, 1, 2, 4, 6 months and 1, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To define the best criteria for a future trial (phase III)</measure>
    <time_frame>2 weeks, 1, 2, 4, 6 months and 1, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To define the best target population for a future study</measure>
    <time_frame>2 weeks, 1, 2, 4, 6 months and 1, 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Ischemia</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group without intervention nor placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose of stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second dose of stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous mesenchymal stem cells</intervention_name>
    <description>Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume&lt;100ml) less than 6 weeks after stroke</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  right or left carotid ischemic stroke in the 14 previous days, confirmed by MRI.

          -  Persistent neurological deficit (NIHSS &gt;=7).

          -  Optimal medical treatment(antithrombotics, antihypertensive, statins).

          -  General state compatible with a program of functional rehabilitation.

        Exclusion Criteria:

          -  Severe extensive stroke implying vital prognosis.

          -  Severe persistent neurological deficit (NIHSS &gt; 24).

          -  Medical history of neurological pathology with a deficit as consequence (Rankin &lt; 3
             before stroke).

          -  Serious psychiatric disease.

          -  Myocardial infarction less than 3 month old.

          -  Recurring thromboembolic disease or less than 6 month old.

          -  Patient with organ transplantation.

          -  Medical history of infection (HIV,HTLV, HBV, HCV).

          -  Current immunosuppressive/immunomodulating treatment.

          -  Medical history of cancer.

          -  Medical history of chemotherapy.

          -  Known chronic kidney failure(clearance of creatinin &lt; 90 ml/min/1,73m2).

          -  Known hepatic failure(diminution of prothrombin level (TP) not corrigiable with
             vitamin K).

          -  Obesity hinding the bone-marrow sampling in the iliac crest.

          -  Pathology implying vital prognosis in the 3 month following stroke.

          -  Refusal to participate.

          -  Patient unable to give personally his/her consent.

          -  Pregnant, parturient and feeding women.

          -  Woman in age to procreate who could not receive an effective method of contraception
             during the study.

          -  Participation to another therapeutic clinical trial or in period of exclusion of a
             therapeutic clinical study.

          -  Privation of liberty with a decision of justice or administration, legal protection.

          -  Non affiliation to social security.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Detante, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neuroradiology/MRI, University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stroke Unit, University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tissular and cell therapy unit, UniversityHospitalof Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Grenoble</investigator_affiliation>
    <investigator_full_name>AdministrateurCIC</investigator_full_name>
    <investigator_title>Dr Olivier DETANTE</investigator_title>
  </responsible_party>
  <keyword>Cell therapy</keyword>
  <keyword>Stroke</keyword>
  <keyword>Neuronal Plasticity</keyword>
  <keyword>Recovery</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

